Latest Breaking News On - Lupin healthcare united kingdom - Page 1 : comparemela.com

Lupin Ltd: Lupin s Namuscla (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)

FOR UK MEDICAL AND TRADE MEDIA ONLY Lupin's Namuscla (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM) Slough

United kingdomSouth africaBen ellisAsia pacificSukaina virjiConsortium for clinical investigation of neurologic channelopathiesNational institute for healthLupin healthcare united kingdomBiotechnology pharmaceuticalsEuropean unionConsilium strategic communicationsNational instituteCare excellenceFinal appraisal determinationGeneral managerLupin healthcare united

Investegate |Lupin Ltd Announcements | Lupin Ltd: Lupin s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)

Investegate announcements from Lupin Ltd, Lupin’s Namuscla® (mexiletine) is recommended by NICE for treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM)

United kingdomSouth africaBen ellisAsia pacificSukaina virjiConsortium for clinical investigation of neurologic channelopathiesNational institute for healthLupin healthcare united kingdomBiotechnology pharmaceuticalsEuropean unionConsilium strategic communicationsNational instituteCare excellenceFinal appraisal determinationGeneral managerLupin healthcare united

Lupin Launches Luforbec® 100/6 μg pMDI, first branded generic alternative to Fostair® 100/6 μg pMDI for treatment of Asthma & COPD, in the UK

Lupin Launches Luforbec® 100/6 μg pMDI, first branded generic alternative to Fostair® 100/6 μg pMDI for treatment of Asthma & COPD, in the UK
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

United kingdomLupin healthcare united kingdomLupin limitedLupin ltdRegulatory agencyLaunches luforbecTime zoneCoral springs

Lupin receives UK marketing authorization for Luforbec® 100/6 μg pMDI for treatment of Asthma & COPD

Lupin receives UK marketing authorization for Luforbec® 100/6 μg pMDI for treatment of Asthma & COPD
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

United kingdomThierry volleVinita guptaLupin healthcare united kingdomLupin limitedRegulatory agencyTime zoneLupin healthcareஒன்றுபட்டது கிஂக்டம்வினிதா குப்தாலூபின் வரையறுக்கப்பட்டவைநேரம் ஸோந்லூபின் சுகாதாரம்

Class 4 Medicines Defect Information, Syonell 250mg Gastro-Resistant Tablets,(PL 35507/0191), Syonell 500mg Gastro-Resistant Tablets, (PL 35507/0192), EL (21)A/11

Brief description of the problem Lupin Healthcare (UK) Limited has informed us of a discrepancy with the product packaging for several batches of Syonell 250mg Gastro-Resistant Tablets and Syonell 500mg Gastro-Resistant Tablets. This discrepancy relates to the incorrect amount of active pharmaceutical ingredient (valproate semisodium) printed on the outer packaging. Labelling on the current packaging Correct labelling on the packaging Syonell 250mg Gastro-Resistant Tablets. Each gastro-resistant tablet contains 250mg of valproate semi sodium Syonell 250mg Gastro-Resistant Tablets. Each gastro-resistant tablet contains 269.06mg of valproate semisodium equivalent to 250mg of valproic acid Syonell 500mg Gastro-Resistant Tablets. Each gastro-resistant tablet contains 500mg of valproate semi sodium

United kingdomLupin healthcare united kingdomPharmacovigilance departmentPharmaceutical ingredientGastro resistant tabletsPatient information leafletsProduct characteristicsMedicines notificationஒன்றுபட்டது கிஂக்டம்மருந்தியல் துறைமருந்து மூலப்பொருள்ப்ராடக்ட் பண்புகள்மருந்துகள் அறிவிப்பு